Adaptive is proud to participate in this collaborative effort. Through this project we are eager to explore how MRD testing can add insight to the clinical assessment of MGUS and SMM patients, and in particular how testing can reduce or alleviate the ongoing uncertainty that so many patients with these diagnoses face. Together with the Foundation for the National Institutes of Health, industry and academic partners, we aim to transform patient care and improve quality of life. Learn more about our project and its potential impact at fnih.org/MMyeRisk. #MultipleMyeloma #BridgestoBreakthroughs
Today, the FNIH Biomarkers Consortium announces the launch of a significant project to develop and validate blood-based biomarkers for predicting progression to multiple myeloma. This collaborative initiative brings together critical resources and stakeholders from the public sector, the private sector, and academia. By creating less invasive and more accurate prediction methods, we aim to enable earlier treatment and improve patient outcomes. Watch to hear more about the project from investigators Irene Ghobrial, MD, Professor of Medicine, Dana-Farber Cancer Institute, and Bruno Paiva, PhD, Co-director, Flow Cytometry Platform & Monoclonal Gammopathies Research Laboratory, University of Navarra. Learn more at fnih.org/MMyeRisk #FNIH #BridgesToBreakthroughs #Biomarkers #BiomarkersConsortium #MultipleMyeloma #CancerResearch Pfizer Regeneron AbbVie
Khushi Matta
1mo
Well done!
Retired Chemistry Teacher at West Linn Wilsonville School District
1moAmazing strides